Stryker Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.0%projected annual EPS growth
Analyst Coverage
25analysts covering
FY Revenue (est.)
$27.3Bnext fiscal year
FY EPS (est.)
$15.01next fiscal year
Monitoring Framework
Key Performance Indicators
Organic Sales Growth Quarterly2.4%Target: 8.0% to 9.5%
Adjusted Gross Margin Quarterly63.6%Target: Expansion through cyber recovery and pricing
Adjusted Operating Margin Quarterly21.1%Target: Expansion through manufacturing absorption normalization
Watch Items
- Cybersecurity Remediation and Deferred Revenue RecoveryTrigger: Full recovery of the estimated $375 million in deferred/lost sales from the March 2026 cyberattackAction: Monitor Q2 and H2 2026 segment results for MedSurg and Neurotechnology to verify shipment normalization.
- Mako SmartRobotics Platform RolloutTrigger: Sustained placement growth of fourth-generation Mako SmartRobotics (Spine and Shoulder)Action: Track Orthopaedics segment volume growth and capital equipment installation rates.
Research as of 2 Sep 2026